[Diabetes: What are the key targets and the objectives? Preserving and protecting a functional pancreatic beta cell mass].
Diabetes is characterized by chronic hyperglycemia. Type 2 diabetes, which represents 90% of diabetes cases, is the consequence of an insulin resistance and pancreatic beta cell dysfunction combination. Since the beta cells are the only cells of the organism to synthesize and to secrete insulin, it is essential to maintain and to protect their function and survival. It is currently proposed that an ideal and innovative treatment of type 2 diabetes should be based on an approach targeting pancreatic beta-cell dysfunction and death. It is now well described that chronic hyperglycemia is critically involved in the development of beta-cell dysfunction and apoptotic death (Glucotoxicity). Reducing the chronic hyperglycemia is a key objective in the treatment of type 2 diabetes, to attenuate not only the development of micro and macrovascular complications, but also the deleterious effects exerted on the pancreatic beta cells.